Molecular prognostic factors in colorectal cancer: 5-year follow-up.

IF 1.2 4区医学 Q4 DEVELOPMENTAL BIOLOGY

Romanian Journal of Morphology and Embryology Pub Date : 2023-01-01 DOI:10.47162/RJME.64.1.08

Alina Elena Ciobanu, Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu

{"title":"Molecular prognostic factors in colorectal cancer: 5-year follow-up.","authors":"Alina Elena Ciobanu, Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu","doi":"10.47162/RJME.64.1.08","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.</p>","PeriodicalId":54447,"journal":{"name":"Romanian Journal of Morphology and Embryology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/e3/RJME-64-1-65.PMC10257784.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian Journal of Morphology and Embryology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47162/RJME.64.1.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.

Abstract Image

查看原文本刊更多论文

结直肠癌的分子预后因素:5年随访。

结直肠癌(CRC)是一种常见病和致死性疾病。发生结直肠癌的风险是由环境和遗传因素决定的。手术治疗是晚期结直肠癌患者的主要治疗方式。近年来，在对肿瘤进行基因分析后，用作靶向治疗的生物制剂得到了特殊的重视:贝伐单抗(Avastin)、西妥昔单抗(Erbitux)、zivaflibercept (Zaltrap)。我们报告了一项基于罗马尼亚克拉约瓦急诊县临床医院外科手术的结直肠癌患者的46例结直肠肿瘤切除标本的研究。组织病理学检查和组织切片免疫组化染色确定侵袭程度。使用Kaplan-Meier检验，我们计算了生存时间与免疫组织化学预后因素之间的相关系数。术后随访60个月。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Romanian Journal of Morphology and Embryology DEVELOPMENTAL BIOLOGY-

CiteScore

1.70

自引率

20.00%

发文量

221

审稿时长

3-8 weeks

期刊介绍： Romanian Journal of Morphology and Embryology (Rom J Morphol Embryol) publishes studies on all aspects of normal morphology and human comparative and experimental pathology. The Journal accepts only researches that utilize modern investigation methods (studies of anatomy, pathology, cytopathology, immunohistochemistry, histochemistry, immunology, morphometry, molecular and cellular biology, electronic microscopy, etc.).